Post on 20-Mar-2018
HEALTH RESEARCH ALLIANCEMEMBERS’ MEETING
Hosted by The Foundation for the National Institutes of Health
Hyatt Regency Bethesda | Bethesda, MarylandSeptember 6-7, 2012
A Case Study on a Ground-Breaking Public-Private Partnership:
NIH/NCATS and Eli Lilly & Company
G. Sitta Sittampalam, PhD (NCATS)Timothy Grese, PhD (Eli Lilly &Co)
Out line
National Center for Advancing Translational Sciences- Goals &Rationale for NCATS (NIH) – Lilly Collaboration- NCATS Mission- NCATS Pharmaceutical Collection (NPC)- A Case Study- The Learning Collaborative (TLC)
Eli Lilly & Co. – Open Innovation Drug Discovery- Establishment & Mission- Phenotypic Drug Discovery (PD2) - Target Drug Discovery Initiative (TargetD2)- Disease pathways of mutual interest.
- Pilot experiment to leverage assets/resources in public-private partnerships- Leverage Lilly Phenotypic Assay Panels – successful in OIDD- Benefits larger drug discovery community- Publish data jointly- build a “collaboration culture”- Collaboration culture = Competencies + Excellence in Science + Trust- Benefit TRND via repurposing NPC compounds
5,000 Years
Lilly-NCATS Collaboration- Goals & Rationale
Accomplishing this effort, even in a few years, makes a lot of sense!
• Screen NPC Collection in Lilly Phenotypic Assay Panels• Jointly publish data –availability to the broader scientific community• Understanding Systems Pharmacology of known drugs• Leverage data for The Rare & Neglected Diseases (TRND) programs
NCATSEstablished: December 23, 2011
Part of consolidated Appropriations Act 2012 (PL112-74)
NCATS Mission“To catalyze the generation of innovative methods and technologies that will enhance the development, testing, and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions
Current Organization
CAN- Cures Acceleration NetworkORDR-Office of Rare Diseases ResearchDPI- Division of Preclinical InnovationDCI- Division of Clinical Innovation
Clinical Translational Science AwardCTSA (Extramural)
NPC Screens at NCGC/NCATS
• NPC Collection has been screened in over 200 assay formats
• Assays represent ~ 25 different disease pathologies
• Examples: - Chronic Lymphocytic Leukemia (CLL)- Acute Myeloid Leukemia (AML) - Niemann-Pick Disease- Type C (NPC)- Transmissible spongiform encephalopathies (TSEs, Prion Disease)- Malaria, Giardia (Neglected Diseases)- Cryptococcal Meningitis
• All projects involves external collaborations with academic/non-profit partners
Chronic Lymphocytic Leukemia
102 molecules: CLL Pan actives vs. Normal B-cells
Doug Auld PhD., Adrien Wiestner MD. et al
From screen completion to clinic in ~17 months!A Rationale for starting the Lilly-NCATS collaboration
Current status - Lilly-NCATS Collaboration
• Publication of NPC collection (Sci. Transl. Med): April 2011
• NCATS- Lilly discussions: June - July 2011
• Collaborative Research Agreement signed: December 2011
• Press release : “NIH and Lilly to generate public resource of approved and investigational medicines” – March 13, 2012
• NCATS- Lilly Scientific and Steering Committees identified – April 2012.
• Compound acquisition and distribution – April-May 2012
• Phenotypic screens initiated at Lilly: July-August 2012
Initial discussions to initiating screens: ~ 12 months.
Lilly Open Innovation Drug Discovery Program
Timothy Grese, PhD.Chief Scientific Officer—Lead Generation and External Innovation
Discovery Chemistry Research and TechnologiesLilly Research Laboratories
Supplementary slides